Polarean's Xenon MRI gains spotlight at ATS 2025 Respiratory Innovation Summit

 () , a leader in advanced MRI lung imaging technology, announced its participation at the American Thoracic Society's 2025 Respiratory Innovation Summit, taking place on May 16-17 in San Francisco. Polarean will also attend the ATS 2025 International Conference from May 18-21.

Polarean is best known for its proprietary Xenon MRI technology XENOVIEW, which uses hyperpolarised Xenon Xe-129 to illuminate hidden lung diseases non-invasively. Polarean's technology has seen rapid sales growth in recent quarters, poised to accelerate further through its growing collaboration with Philips.

's selection as a featured company at RIS 2025 further underscores the growing recognition of its Xenon MRI platform as a tool for clinical imaging and drug development. At the ATS 2025 International Conference, Xenon MRI will be featured in over 30 posters and presentations from more than 10 leading clinical sites. The volume and depth of research presented underscores the technology's expanding role in clinical trials and lasting impact on pulmonary care.

Christopher von Jako, CEO of Polarean, commenting: "We are honoured to return as a featured company at the Respiratory Innovation Summit. RIS and the ATS International Conference provide vital opportunities to engage with thought leaders, strengthen partnerships, and highlight the growing body of clinical evidence supporting Xenon MRI. With over 30 presentations this year, it's clear that Xenon MRI is not only gaining traction-it's shaping the future of functional lung imaging and respiratory care."

View from Vox

Polarean's Xenon MRI technology continues to gain momentum. After tripling revenues in FY24 and commencing the next phase of its collaboration with Philips, the company today confirmed its participation at the prestigious ATS Respiratory Innovation Summit and ATS International Conference in May, 2025. Polarean will be a major featured company at both events, being significant opportunities to convey the effectiveness of the technology to participating clinicians, researchers, industry partners, and patient advocates.

As mentioned, Polarean's Xenon MRI platform promises to revolutionise medical imaging with the ability to illuminate hidden diseases non-invasively. 's presentations will highlight Xenon MRI's versatility across a wide spectrum of respiratory conditions, including asthma, bronchopulmonary dysplasia, COPD, Covid-19, cystic fibrosis, pulmonary arterial hypertension, radiation-induced lung injury, and post-transplant lung monitoring.

On May 14, 2025, Polarean announced the next stage of its ongoing collaboration with Philips, as the two companies partnered to bring advanced Xenon lung MRI to more children with chronic obstructive lung disease. The radiation-free MRI technology can help doctors see how air moves in the lungs, offering a safer, clearer view of lung function for children as young as 6, pending FDA approval. Xenon MRI is already FDA-approved for adults and children aged 12 and older.

There is a clear unmet need for safe, accurate, and non-invasive imaging tools to visualise lung ventilation without radiation exposure. Obstructive lung diseases like asthma and COPD affect over 42 million people in the US and more than 500 million worldwide, placing a major burden on global respiratory health. This is particularly urgent in pediatrics, where repeat imaging is often necessary to track disease progression or treatment response.

Polarean's technology is now integrated into Philips' clinical workflow across 3.0T MRI systems - with just two 10-second breath-holds, the scan session can be completed in under one minute, using the Polarean XENOVIEW 3T Chest Coil. 's revenue more than tripled in FY24 to $3.1m across 22 active customers, beating guidance. Backed by a $12.6m fundraising round led by strategic partners, the company's current cash runway should extend until at least Q2 2026.

Follow News & Updates from Polarean Imaging: